Vilya builds a proprietary computational drug design and development platform that uses advanced machine learning and generative AI to design de novo molecular structures. The company focuses on novel macrocycles—molecules sized between small molecules and antibodies—to target previously difficult-to-drug therapeutic targets. It is advancing a pipeline of these macrocycles intended to precisely target disease biology. Vilya intends to use new funding to accelerate both its platform development and its therapeutic pipeline. The company’s scientific leadership includes David Baker, Ph.D., and its executive team includes CEO Cyrus Harmon, Ph.D., Chief Scientific Officer Katerina Leftheris, Ph.D., Co‑Founder and CTO Patrick Salveson, Ph.D., and Co‑Founder and VP Business Development Inca Dieterich, Ph.D. Vilya has operations in Seattle and South San Francisco. Vilya operates a proprietary platform powered by advanced machine learning to design de novo molecular structures that sit between small molecules and antibodies. The company’s artificial, biologic‑like molecules are engineered to be membrane‑permeable, disrupt protein‑protein interactions, and be highly selective for their targets. IPD scientists published a Cell paper describing accurate de novo design of membrane‑traversing macrocycles that underpin Vilya’s foundational technology. Vilya intends to leverage this computational design capability to pursue previously difficult‑to‑drug therapeutic targets across a broad set of indications. The company launched in Seattle with $50 million in committed Series A financing led by ARCH Venture Partners. Its co‑founding team combines researchers from the Institute of Protein Design and leaders from ARCH Venture Partners.

Total raised

$121M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2024